Significance of platelet activation in vascular access survival of haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 18, Issue 5, 2003, Pages 947-954

  Chuang, Yao Cheng ^a   Chen, Jin Bor ^a   Yang, Lin Cheng ^a   Kuo, Ching Yuan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

CD62P; Haemodialysis; PAC 1; Platelet activation; Platelet derived microparticles; Vascular access survival

Indexed keywords

FIBRINOGEN RECEPTOR; PADGEM PROTEIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD VESSEL GRAFT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; THROMBOCYTE ACTIVATION; THROMBOCYTE KINETICS; VASCULAR ACCESS;

ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD PLATELETS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; RECEPTORS, FIBRINOGEN; RENAL DIALYSIS; UREMIA;

EID: 0038025588     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg056     Document Type: Article

References (24)

1. Windus DW. Permanent vascular access: a nephrologist's view. Am J Kidney Dis 1993; 21: 457-471
2. Hakim R, Himmelfarb J. Hemodialysis access failure: a call to action. Kidney Int 1998; 54: 1029-1040
3. Domoto DT, Bauman JE, Joist JH. Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. Thromb Res 1991; 62: 737-743
4. Yardumian DA, Mackie IJ, Machin SJ. Laboratory investigation of platelet function: a review of methodology. J Clin Pathol 1986; 39: 701-712
5. Parbtani A, Frampton G, Yewdall V, Kasai N, Cameron JS. Platelet and plasma serotonin in glomerulonephritis. III: The nephritis of systemic lupus erythematosus. Clin Nephrol 1980; 14: 164-172
6. McEver RP, Martin MN. A monoclonal antibody to a membrane glycoprotein binds only to activated platelet. J Biol Chem 1984;259:9799-9804
7. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1393-1401
8. de Zoppo GJ. The role of platelet activation in ischemic stroke. Neurology 1998; 51 [Suppl 3]: S9-S14
9. FitzGerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989
10. Tschoepe D, Roesen P, Schwippert B, Gries FA. Platelet in diabetes: the role in the hemostatic regulation in atherosclerosis. Semi Thromb Hemost 1993; 19: 122-128
11. Gresele P, Catalano M, Giammrresi C et al. Platelet activation markers in patients with peripheral arterial disease - a prospective comparison of different platelet function test. Thromb Hemost 1997; 78: 1434-1437
12. Sirolli V, Strizzi L, Stante SD, Robuffo I, Procopio A, Bonomini M. Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis. Thromb Hemost 2001; 86: 834-839
13. Bonomini M, Reale M, Santarelli P, Stuard S, Settefrati N, Albertazzi A. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron 1998; 79: 399-407
14. Wu KK. Platelet activation mechanisms and markers in arterial thrombosis. J Int Med 1996; 239: 17-34
15. George JN, Pickett EB, Saucerman S et al. Platelet surface glycoproteins: studies on resting and activated platelets and platelet membrane microparticles in normal subject, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78: 340-348
16. Zibari GB, Rohr MS, Landereneau MD et al. Complication from permanent hemodialysis access. Surgery 1998; 104: 681-686
17. Omoto S, Nomura S, Shouzu A et al. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron 1998; 81: 271-277
18. Carcia-Martin F, de Arriba G, Carrascosa T, Moldenhauer F, Martin-Escobar E. Anticardiolipin antibodies and lupus anti-coagulant in end-stage renal disease. Nephol Dial Transplant 1991; 6: 543-547
19. Churchill DN, Taylor DW, Cook RJ et al. Canadian Hemodialysis Morbidity Study. Am J Kidney Dis 1992; 19: 214-234
20. Windus DW. The effect of comorbid conditions on hemodialysis access patency. Adv Renal Replac Ther 1994; 1: 148-154
21. Ludlam CA. Evidence for the platelet specificity of β-thromboglobulin and studies on its plasma concentration in healthy individuals. Br J Haematol 1979; 41: 271-278
22. Goldwasser P, Michel M, Collier J. Prealbumin and lipoprotein(a) in hemodialysis: relationships with patient and vascular access survival. Am J Kidney Dis 1993; 22: 215-225
23. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptors for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-18212
24. Gilbert GE, Sim PJ, Wiedmer T, Furie B, Furie BC, Shattil SJ. Platelet-derived microparticles express high affinity receptors for factor VIIIa. J Biol Chem 1991; 266: 17261-17268